# Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

> **NCT04264078** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 30 (estimated)

## Conditions studied

- T-cell Leukemia
- T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD7 UCAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cytoxan
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT04264078
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04264078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04264078, "Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04264078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*